Jinghua Pharmaceutical Co., Ltd. (002349)
Market Closed
7 Aug, 06:57
XSHE XSHE Primary ¥
6. 87
+0.21
+3.1532%
¥
6.67B Market Cap
- P/E Ratio
0.31% Div Yield
18.06M Volume
- Eps
¥ 6.66
Previous Close Want to track 002349 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
002349 closed Friday higher at ¥6.87, an increase of 3.1532% from Thursday's close, completing a monthly increase of 10.628% or ¥0.66. Over the past 12 months, 002349 stock lost -5.8904%.
002349 pays dividends to its shareholders, with the most recent payment made on May 29, 2026. The next estimated payment will be in In 9 months on May 29, 2027 for a total of ¥0.09.
The last earnings report, released on May 16, 2025, exceeded the consensus estimates by 0.0764%. On average, the company has surpassed earnings expectations by 0.0837%, based on the last three reports.
Jinghua Pharmaceutical Co., Ltd. has completed 5 stock splits, with the recent split occurring on Mar 14, 2017.
The company's stock is traded on one exchange.
Jinghua Pharmaceutical Co., Ltd. (002349) FAQ
What is the stock price today?
The current price is ¥6.87.
On which exchange is it traded?
Jinghua Pharmaceutical Co., Ltd. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 002349.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.31%.
What is its market cap?
As of today, the market cap is 6.67B.
Has Jinghua Pharmaceutical Co., Ltd. ever had a stock split?
Jinghua Pharmaceutical Co., Ltd. had 5 splits and the recent split was on Mar 14, 2017.
Jinghua Pharmaceutical Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Jian Cheng CEO | XSHE Exchange | CNE100000L14 ISIN |
| CN Country | 1,490 Employees | 29 May 2026 Last Dividend | 14 Mar 2017 Last Split | 3 Feb 2010 IPO Date |
Overview
Jinghua Pharmaceutical Group Co., Ltd., originally known as Nantong Jinghua Pharmaceutical Co., Ltd., is a prominent player in the pharmaceutical sector in China, with a focus on the research and development, manufacturing, and distribution of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. Since its inception in 1957, Jinghua has established itself as a reputable source in the industry, serving national and potentially international markets from its base in Nantong, China.
Products and Services
- Phenylbutazone: An anti-inflammatory API used for the treatment of pain and fever, particularly in the management of ankylosing spondylitis and rheumatoid arthritis.
- Primidone: Used primarily as an anticonvulsant, Primidone is effective in managing and controlling seizures in epilepsy.
- Phenobarbital: One of the oldest and most widely used anticonvulsants for the treatment of epilepsy. It also serves as a sedative in lower doses.
- Fluorouracil: A chemotherapy medication used to treat various types of cancer, including colon cancer, breast cancer, and skin cancer, by interfering with the cell's DNA synthesis.
- Propylthiouracil: Primarily used in the treatment of hyperthyroidism, it acts by decreasing the amount of thyroid hormone produced by the thyroid gland.
- Piroxicam: A nonsteroidal anti-inflammatory drug (NSAID) effective in treating pain and inflammation associated with arthritis.
- Flucytosine: An antifungal medication used in the treatment of serious fungal infections by inhibiting fungal DNA and RNA synthesis.
Contact Information
Address: No 20, 3 Haibin Road, Nantong, China, 226407
Phone: 86 513 8560 9405
Website: https://www.jinghuapharm.com
